000131869 001__ 131869
000131869 005__ 20240219150722.0
000131869 0247_ $$2doi$$a10.3390/vaccines12020126
000131869 0248_ $$2sideral$$a136997
000131869 037__ $$aART-2024-136997
000131869 041__ $$aeng
000131869 100__ $$0(orcid)0000-0003-2313-2762$$aHernández-García, Ignacio$$uUniversidad de Zaragoza
000131869 245__ $$aCOVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis
000131869 260__ $$c2024
000131869 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131869 5203_ $$aOur objective was to know the COVID-19 vaccination coverage in multiple sclerosis (MS) patients and its factors associated. A retrospective cohort study was carried out. Patients seen at the MS unit of the University Clinical Hospital of Zaragoza between 2017 and 2021 were included. Variables were obtained by reviewing the specialized and primary care records. Associations between receiving COVID-19 full primo-vaccination, as well as one booster dose since autumn 2022, and the other variables were analyzed using bivariate analysis and multiple logistic regression models. Of the 359 included patients, 90.3% received the COVID-19 full primo-vaccination. Having been born in Spain (aOR = 3.40) and having received the 2020–2021 influenza vaccine (aOR = 6.77) were associated with receiving the COVID-19 full primo-vaccination. Vaccination with a COVID-19 booster dose was detected in 141 patients (39.3%). Sex (man) (aOR = 2.36), age (60 years or over) (aOR = 6.82), type of MS (Primary Progressive/Secondary Progressive) (aOR = 3.94), and having received the 2022–2023 influenza vaccine (aOR = 27.54) were associated with receiving such a booster dose. The COVID-19 booster dose was administered at the same time as the 2022–2023 influenza vaccine in 57.8% (67/116) of the patients vaccinated with both vaccines. The COVID-19 full primo-vaccination coverage is higher than in other countries. However, the decrease in vaccination coverage with the booster dose makes it necessary to develop strategies to improve it that are not limited to administering the flu vaccine together with the COVID-19 booster dose. Such strategies should be in focus, especially for women under 60 years of age.
000131869 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131869 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131869 700__ $$aRodríguez-Montolio, Joana
000131869 700__ $$aAlmeida-Zurita, Monserrath
000131869 700__ $$aCheli-Gracia, Dionisio
000131869 700__ $$aMoral Sahuquillo, Belén del
000131869 700__ $$0(orcid)0000-0001-9714-8105$$aAibar-Remón, Carlos$$uUniversidad de Zaragoza
000131869 700__ $$0(orcid)0000-0002-1756-5492$$aGarcés-Redondo, Moisés$$uUniversidad de Zaragoza
000131869 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131869 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000131869 773__ $$g12, 2 (2024), 126 [15 pp.]$$tVaccines$$x2076-393X
000131869 8564_ $$s317086$$uhttps://zaguan.unizar.es/record/131869/files/texto_completo.pdf$$yVersión publicada
000131869 8564_ $$s2765438$$uhttps://zaguan.unizar.es/record/131869/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131869 909CO $$ooai:zaguan.unizar.es:131869$$particulos$$pdriver
000131869 951__ $$a2024-02-19-13:29:17
000131869 980__ $$aARTICLE